Your browser doesn't support javascript.
loading
Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase.
Garvie, Colin W; Wu, Xiaoyun; Papanastasiou, Malvina; Lee, Sooncheol; Fuller, James; Schnitzler, Gavin R; Horner, Steven W; Baker, Andrew; Zhang, Terry; Mullahoo, James P; Westlake, Lindsay; Hoyt, Stephanie H; Toetzl, Marcus; Ranaghan, Matthew J; de Waal, Luc; McGaunn, Joseph; Kaplan, Bethany; Piccioni, Federica; Yang, Xiaoping; Lange, Martin; Tersteegen, Adrian; Raymond, Donald; Lewis, Timothy A; Carr, Steven A; Cherniack, Andrew D; Lemke, Christopher T; Meyerson, Matthew; Greulich, Heidi.
Afiliación
  • Garvie CW; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Wu X; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Papanastasiou M; Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Lee S; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Fuller J; Helix Biostructures, Indianapolis, IN, USA.
  • Schnitzler GR; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Horner SW; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Baker A; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Zhang T; Thermo Fisher, San Jose, CA, USA.
  • Mullahoo JP; Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Westlake L; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Hoyt SH; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Toetzl M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Ranaghan MJ; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • de Waal L; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • McGaunn J; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Kaplan B; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Piccioni F; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Yang X; Merck Research Laboratories, Boston, MA, USA.
  • Lange M; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Tersteegen A; Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany.
  • Raymond D; NUVISAN ICB GmbH, Berlin, Germany.
  • Lewis TA; Research and Development, Pharmaceuticals, Bayer AG, Wuppertal, Germany.
  • Carr SA; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Cherniack AD; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Lemke CT; Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Meyerson M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Greulich H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nat Commun ; 12(1): 4375, 2021 07 16.
Article en En | MEDLINE | ID: mdl-34272366
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridazinas / Péptidos y Proteínas de Señalización Intracelular / Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3 Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridazinas / Péptidos y Proteínas de Señalización Intracelular / Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3 Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos